In addition, we showed that systemic delivery of anti-FLT1 peptides and monoclonal antibodies (MAbs) in mdx mice recapitulated the reduction in DMD-associated pathology seen after Flt1 deletion in mdx mice, validating Flt1 as a therapeutic target for the treatment of DMD. This evidence concerns the gene FLT1 and Duchenne muscular dystrophy.